It is an absolute necessity to achieve complete control of comorbidities to obtain optimal asthma control. Importantly, type 2 asthma and ECRS share the same inflammatory pathophysiology and are common co-morbidities. If the initial biologic is insufficiently effective, it is worth considering an alternative biologic.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11325252 | PMC |
http://dx.doi.org/10.1002/rcr2.70009 | DOI Listing |
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!